SCHEMBL9923006

SCHEMBL9923006

CNc1ccc2c(=O)n(-c3c(F)cc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3C(F)(F)F)cnc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 2/20 0.46
FBP1 P09467 1/20 0.37
PTPN2 P17706 4/20 0.35
PTPN1 P18031 4/20 0.35
PTPN5 P54829 4/20 0.35
WEE1 P30291 1/20 0.33
RAF1 P04049 2/20 0.33
MAPK3 P27361 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
MAPT P10636 3/20 0.33
HSPD1 P10809 2/20 0.32
HSPE1 P61604 2/20 0.32
EPHB4 P54760 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
APP P05067 1/20 0.30
CSF1R P07333 1/20 0.30
PPARG P37231 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922998 0.93 P2RY12 (0.50) P2RY12FBP1PTPN2PTPN1PTPN5
SCHEMBL14228650 0.93 P2RY12 (0.38) P2RY12FBP1WEE1RAF1MAPK3
SCHEMBL12161672 0.91 P2RY12 (0.48) P2RY12FBP1WEE1MAPTCSF1R
SCHEMBL9923000 0.90 P2RY12 (0.47) P2RY12FBP1WEE1MAPTCSF1R
SCHEMBL9923001 0.89 P2RY12 (0.46) P2RY12FBP1PTPN2PTPN1PTPN5
SCHEMBL12177255 0.88 P2RY12 (0.46) P2RY12FBP1MAPTCSF1R
SCHEMBL9922992 0.87 P2RY12 (0.47) P2RY12FBP1PTPN2PTPN1PTPN5
SCHEMBL9922343 0.86 P2RY12 (0.51) P2RY12FBP1MAPTCSF1R
SCHEMBL12177675 0.85 P2RY12 (0.41) P2RY12FBP1EPHB4CA9CSF1R
SCHEMBL12177657 0.85 P2RY12 (0.42) P2RY12FBP1WEE1MAPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-7358257-B2 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents PORTOLA PHARMACEUTICALS, INC. (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885FBP1 1584/4885PTPN2 383/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885FBP1 1579/4885PTPN2 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.